Muhammad Jawad Popalzai

Muhammad Popalzai practices at SIH Memorial Hospital of Carbondale in Carbondale, Illinois, part of Southern Illinois Healthcare.

Muhammad Popalzai's NPI, 1003051871, was assigned on December 9, 2008. Muhammad Popalzai holds Illinois license 036133368.

Muhammad Popalzai's primary practice is SIH Memorial Hospital of Carbondale, at 405 W Jackson, Carbondale, IL 62901 in Jackson County. The practice phone is (618) 549-0721.

Muhammad Popalzai's primary practice is SIH Memorial Hospital of Carbondale in Carbondale, Illinois, part of Southern Illinois Healthcare. Muhammad Popalzai is also affiliated with SIH Herrin Hospital. The medical group on file is Southern Illinois Healthcare (SIH). Dmand AI also links Muhammad Popalzai to 2 more hospitals, 1 group practice or clinic and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Muhammad Popalzai practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Muhammad Popalzai's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Muhammad Popalzai is board certified in hematology by the American Board of Internal Medicine. Muhammad Popalzai is licensed in Illinois.

CMS data shows 1,143 Medicare services from Muhammad Popalzai across 5 procedure codes in 2024, for 334 Medicare patients. Medicare paid $78,767 for them.

CMS counts 334 Medicare patients who saw Muhammad Popalzai in 2024. The largest group is 65 to 74, with 131 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 30% are also on Medicaid. Their average risk score is 2.23, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Muhammad Popalzai's median patient age at 74, with 56% women.

In 2024, Muhammad Popalzai wrote 1,533 Medicare Part D claims for 259 patients. 78% of them were for generic drugs. CMS names the drug for 1,256 of them, across 39 drugs with 11 or more claims each, at $3,401,811 in total drug cost. In 2023, CMS named 1,238 claims across 40 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Muhammad Popalzai for performance year 2024, reported as part of a group. Muhammad Popalzai accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Muhammad Popalzai as offering telehealth.

Dmand AI links 7 papers to Muhammad Popalzai, published from 2010 to 2022. 2012 was the busiest year, with 2. Muhammad Popalzai's most frequent co-authors are Nelly Antoine Aoun, MD, Vijaya Raj Bhatt, MD and Qun Dai, MD.

Dmand AI links Muhammad Popalzai to 10 clinical trials, 4 of them phase 2 studies. 9 are still active or recruiting. Conditions studied include Adenocarcinoma of Lung, Biliary Atresia and Low Back Pain.

CMS Open Payments shows 95 general payments to Muhammad Popalzai from 27 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 87% of the total. Amgen Inc. paid the most, $466.